Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | casein kinase II, putative | 0.0477 | 1 | 0.5 |
Loa Loa (eye worm) | CMGC/CK2 protein kinase | 0.0477 | 1 | 1 |
Echinococcus multilocularis | casein kinase ii subunit alpha | 0.0477 | 1 | 1 |
Trypanosoma brucei | Casein kinase II | 0.0477 | 1 | 1 |
Schistosoma mansoni | protein kinase | 0.0477 | 1 | 1 |
Toxoplasma gondii | CMGC kinase, CK2 family | 0.0477 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0477 | 1 | 0.5 |
Echinococcus granulosus | casein kinase ii subunit alpha | 0.0477 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0477 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0477 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0477 | 1 | 0.5 |
Plasmodium falciparum | casein kinase 2, alpha subunit | 0.0477 | 1 | 0.5 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0477 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0477 | 1 | 0.5 |
Entamoeba histolytica | casein kinase, putative | 0.0477 | 1 | 0.5 |
Loa Loa (eye worm) | CAMK/CAMKL/PASK protein kinase | 0.0282 | 0.5599 | 0.3748 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0477 | 1 | 0.5 |
Plasmodium vivax | casein kinase 2, alpha subunit, putative | 0.0477 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0477 | 1 | 0.5 |
Onchocerca volvulus | 0.0282 | 0.5599 | 1 | |
Giardia lamblia | Kinase, CMGC CK2 | 0.0477 | 1 | 0.5 |
Leishmania major | casein kinase II, putative | 0.0477 | 1 | 0.5 |
Plasmodium vivax | unspecified product | 0.0477 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 0 % | Neuroprotective activity against mouse HT22 cells assessed as inhibition of HCA-induced cell injury pretreated at 30 uM for 30 mins measured after 24 hrs by MTT assay | ChEMBL. | 23973819 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.